NASDAQ:SMMT Summit Therapeutics Q2 2025 Earnings Report $14.13 +0.12 (+0.86%) Closing price 06/15/2026 04:00 PM EasternExtended Trading$14.20 +0.06 (+0.46%) As of 08:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Summit Therapeutics EPS ResultsActual EPS-$0.76Consensus EPS -$0.10Beat/MissMissed by -$0.66One Year Ago EPSN/ASummit Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASummit Therapeutics Announcement DetailsQuarterQ2 2025Date8/11/2025TimeBefore Market OpensConference Call DateMonday, August 11, 2025Conference Call Time7:00AM ETUpcoming EarningsSummit Therapeutics' Q2 2026 earnings is estimated for Monday, August 10, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, August 4, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Summit Therapeutics Earnings HeadlinesMahkam Zanganeh Acquires 3,810,000 Shares of Summit Therapeutics (NASDAQ:SMMT) StockJune 14 at 5:23 AM | americanbankingnews.comRobert Duggan Purchases 3,810,000 Shares of Summit Therapeutics (NASDAQ:SMMT) StockJune 14 at 5:23 AM | americanbankingnews.comVWAV: The Defense Tech Story Going Unnoticed!As global defense spending accelerates, VisionWave Holdings (NASDAQ: VWAV) is developing a full-stack intelligence platform integrating AI analytics, RF sensing, autonomous systems, and high-performance computing for modern military and homeland security applications. Recent milestones include a provisional patent for its xCalibre AI vision platform, an initial commercial homeland security order, and a strategic AI vision IP acquisition reportedly valued at approximately $60 million. The company is also preparing to unveil DeepWave RF at AOW Energy 2026 in September.June 16 at 1:00 AM | Equiscreen (Ad)Summit Therapeutics PLC (NASDAQ:SMMT) Given Average Rating of "Hold" by BrokeragesJune 14 at 4:49 AM | americanbankingnews.comWhy is SMMT stock tumbling today?June 10, 2026 | msn.comSummit Therapeutics Announces Proposed Public Offering of Common StockJune 9, 2026 | businesswire.comSee More Summit Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Summit Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Summit Therapeutics and other key companies, straight to your email. Email Address About Summit TherapeuticsSummit Therapeutics (NASDAQ:SMMT) is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies. Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S. Food and Drug Administration. Alongside its infectious disease program, Summit has explored small‐molecule therapies for rare genetic disorders, leveraging its drug discovery capabilities to identify compounds that modulate disease‐relevant pathways. Founded in 2003 and headquartered in Oxford, England, Summit maintains operations in North America to support clinical development and regulatory activities across the United States and Europe. The company’s management team brings extensive experience in biopharmaceutical research, clinical operations, and commercialization strategy, with a commitment to advancing its pipeline toward regulatory approval and broad patient access.View Summit Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Dividend Increases Investors Can Actually TrustRH’s Strong Q1 Still Leaves Investors With One Big QuestionAdobe Stock Just Got Cheaper—Is Wall Street Missing the Story?3 AI Stocks With Moats That Could Outlast Summer VolatilityViasat's Orbiting Profits: Space Force Jackpot?What to Expect From Q2 Earnings as Tech Strength BroadensTJX: Retail’s Apex Predator Feasts on Inflation Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
